2017 Cell & Gene Therapy Speakers Include:Rahul Aras, President, Co-founder & CEO
Juventas Therapeutics David Sourdive, Co-founder, Executive Vice President
Cellectis Sven Kili, Vice President and Head of Gene Therapy Development
GlaxoSmithKline Cedrik Britten, Vice President & Head of Oncology Cell Therapy DPU
GlaxoSmithKline Markwin Velders, Vice President, Operations
Kite Pharma Gwendolyn Binder-Scholl, Chief Technology Officer
Adaptimmune Ajan Reginald, Executive Director & Co-founder
Cell Therapy Ltd Sylvain Arnould, Process Development & Production Director
Celyad Alex Bloom, Director, Global Regulatory Affairs
CellMedica Michael Mercaldi, Director, Purification Process Development and Manufacturing
Codiak Biosciences Joachim Scholpp, Global Head of Clinical Pharmacology Program Leadership
Boehringer Ingelheim Katherine Tsokas, Regulatory Head of Regenerative Medicine & Advanced Therapy
Janssen Research & Development Tanvir Tabish, Head of Drug Product Development for Gene Therapy and Coagulation Factors
Shire Nitza Thomasson, Chief Preclinical Officer
Gensight Biologics Emily Culme-Seymour, External Strategy Manager, Gene Therapy, Rare Diseases Unit, R&D
GlaxoSmithKline Juliana Woda, Project Manager
BioMotiv Verena Vanessa Fischer, Lab Head in Early Stage Bioprocess Development
Boehringer Ingelheim Monicah Otieno, Director of Mechanistic & Investigative Toxicology
Janssen David Schaffer, Director
Berkeley Stem Cell Center, University of California, Berkeley
|